Comparability of Anti-CKAP4 (VS38c Clone) and Anti-CD38 Multiepitope Antibody Reagents in Multiple Myeloma Patients Treated with Daratumumab

Agilent Dako



Expression of the intracellular CKAP4 protein is unaffected by daratumumab treatment, offering a promising alternative to the surface marker CD38 targeted by anti-CD38 antibody therapies.

An educational note on the study from Broijl and colleagues published by the American Journal of Clinical Pathology in 2021.

Insights

- The use of VS38c as alternative to CD38 multiepitope (CD38-ME) in Euroflow's multiple myeloma (MM) panels is in full concordance with MRD levels in patients treated with or without daratumumab
- The availability of VS38c will facilitate identification of MM cells in patients where the CD38 antigen is masked, suppressed or even lost due to treatment with daratumumab or other CD38-targeted therapies
- VS38c is a promising alternative marker for the identification of MM cells in an Euroflow panel setup

Agilent

Comparability of anti-CKAP4 (VS38c) and anti-CD38-ME reagent antibodies *(Broijl et al., 2021)*



References

1. Broijl et al. (2021) VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma. *Am J Clin Pathol.* aqab163.
2. Saltarella et al. (2020) Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. *Cells* 9(1):1-14.

Please contact us for more details:
rpsupport@agilent.com

29570 D69896_02 2023JAN02

Agilent
Trusted Answers